Compare AMBA & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMBA | PBLS |
|---|---|---|
| Founded | 2004 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.4B |
| IPO Year | 2011 | 2026 |
| Metric | AMBA | PBLS |
|---|---|---|
| Price | $62.24 | $28.42 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $97.25 | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 545.1K |
| Earning Date | 05-28-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.32 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $295,402,000.00 | N/A |
| Revenue This Year | $15.03 | N/A |
| Revenue Next Year | $12.41 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $48.30 | $25.56 |
| 52 Week High | $96.69 | $33.65 |
| Indicator | AMBA | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 41.03 | 52.17 |
| Support Level | $49.58 | $26.96 |
| Resistance Level | $71.02 | $30.90 |
| Average True Range (ATR) | 7.99 | 2.39 |
| MACD | -1.33 | -0.05 |
| Stochastic Oscillator | 9.15 | 30.56 |
Ambarella Inc is a developer of low-power system-on-a-chip, or SoC, semiconductors and software for edge and physical artificial intelligence (AI) applications and intelligent automation. Its products are used in a wide variety of human viewing, computer vision for edge and physical AI applications, including a variety of video security cameras, automotive camera systems, fixed robots, autonomous mobile robots (AMRs), industrial applications, intelligent transportation systems, and consumer devices, such as action, drone and 360 degree cameras. The company operates as a single operating and reportable segment and derives substantially all of its revenue from development and sales of low-power AI-based processing and video and image processing SoC solutions.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.